Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

von Momtaz, Parisa, Postow, Michael A
Veröffentlicht in Pharmgenomics Pers Med (2014)

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

von Kyi, Chrisann, Postow, Michael A
Veröffentlicht in Immunotherapy (2016)

Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications

von Postow, Michael A, Robson, Mark E
Veröffentlicht 2012

Combinations of Radiotherapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes

von Barker, Christopher A., Postow, Michael A.
Veröffentlicht in Int J Radiat Oncol Biol Phys (2014)

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

von Friedman, Claire F., Postow, Michael A.
Veröffentlicht in Curr Oncol Rep (2016)

Recent advances in understanding antitumor immunity

von Munhoz, Rodrigo Ramella, Postow, Michael Andrew
Veröffentlicht in F1000Res (2016)

Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone

von Rosner, Samuel, Sen, Filiz, Postow, Michael
Veröffentlicht in J Immunother Cancer (2017)

A step forward for patients with NRAS-mutant melanoma

von Postow, Michael A., Chapman, Paul B.
Veröffentlicht in Lancet Oncol (2017)

Clinical development of PD-1/PD-L1 in Advanced Melanoma

von Munhoz, Rodrigo Ramella, Postow, Michael Andrew
Veröffentlicht in Cancer J (2018)

Beyond Cancer Vaccines: A Reason for Future Optimism with Immunomodulatory Therapy

von Postow, Michael, Callahan, Margaret K., Wolchok, Jedd D.
Veröffentlicht 2011

Targeting Immune Checkpoints: Releasing the Restraints on Anti-tumor Immunity for Patients with Melanoma

von Postow, Michael A., Harding, James, Wolchok, Jedd D.
Veröffentlicht 2012

Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-Oncology Research

von Kidwell, Kelley M, Postow, Michael A., Panageas, Katherine S.
Veröffentlicht in Clin Cancer Res (2017)

Immunomodulatory Therapy for Melanoma: Ipilimumab and Beyond

von Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Veröffentlicht 2013

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

von Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Veröffentlicht in Front Oncol (2015)

Immune Checkpoint Blockade in Cancer Therapy

von Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D.
Veröffentlicht in J Clin Oncol (2015)

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

von Weber, Jeffrey S., Postow, Michael, Lao, Christopher D., Schadendorf, Dirk
Veröffentlicht in Oncologist (2016)

Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy In Need of Further Investigation

von Escorcia, Freddy E., Postow, Michael A., Barker, Christopher A.
Veröffentlicht in Cancer J (2017)

Ipilimumab in patients with melanoma and autoimmune disease

von Kyi, Chrisann, Carvajal, Richard D, Wolchok, Jedd D, Postow, Michael A
Veröffentlicht 2014

Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions

von Page, David B., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D.
Veröffentlicht 2013

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

von Ryder, Mabel, Callahan, Margaret, Postow, Michael A, Wolchok, Jedd, Fagin, James A
Veröffentlicht in Endocr Relat Cancer (2014)